ScoreWhy is Carisma Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 18.53% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -46.94
2
With a growth in Net Sales of 1236.78%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -22.41 MM
- NET SALES(HY) Higher at USD 45.25 MM
- DEBTORS TURNOVER RATIO(HY) Highest at 64.34 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -90.78%, its profits have risen by 114.1%
4
Majority shareholders : Mutual Funds
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -90.78% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Carisma Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Carisma Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Carisma Therapeutics, Inc.
-85.23%
-0.22
443.27%
S&P 500
30.29%
0.62
19.30%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
36.17%
EBIT Growth (5y)
18.53%
EBIT to Interest (avg)
-46.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
-4.66
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.67%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
0
Industry P/E
Price to Book Value
-1.59
EV to EBIT
-0.10
EV to EBITDA
-0.08
EV to Capital Employed
0.30
EV to Sales
-0.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-310.71%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend35What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -22.41 MM
NET SALES(HY)
Higher at USD 45.25 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 64.34 times
OPERATING PROFIT(Q)
Highest at USD 43.81 MM
PRE-TAX PROFIT(Q)
Highest at USD 44.72 MM
NET PROFIT(Q)
Highest at USD 44.72 MM
EPS(Q)
Highest at USD 1.07
-3What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 101.29% (YoY
CASH AND EQV(HY)
Lowest at USD 4.78 MM
DEBT-EQUITY RATIO
(HY)
Highest at 232.41 %
Here's what is working for Carisma Therapeutics, Inc.
Net Sales
At USD 45.25 MM has Grown at 259.64%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 44.72 MM has Grown at 452.05%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 44.72 MM has Grown at 452.05%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -22.41 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 45.25 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Operating Profit
Highest at USD 43.81 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 44.72 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 44.72 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 1.07
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 64.34 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Carisma Therapeutics, Inc.
Cash and Eqv
Lowest at USD 4.78 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 232.41 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 101.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
